Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
Title:
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
Author:
Joshi, Kroopa Muhith, Abdul Obeid, Mariam Milner-Watts, Charlotte Yousaf, Nadia Popat, Sanjay Davidson, Michael Bhosle, Jaishree O’Brien, Mary Minchom, Anna